Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication

Executive Summary

Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.

Advertisement

Related Content

Japan Approval Another Boost For Tagrisso in 1L NSCLC
Sub Q Maintenance Success Set To Improve Entyvio's Position In Ulcerative Colitis
PACIFIC Pays Off Again For AZ With Imfinzi Lung Cancer OS Success
Takeda Looks To The New As It Braces For Velcade Generics
Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123417

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel